Cancer News and Research

Latest Cancer News and Research

Noninvasive diagnostics may offer alternative to liver biopsy for assessing liver fibrosis

Patients who are evaluated for liver diseases such as hepatitis C (HCV) are typically recommended for liver biopsy to determine the extent of disease progression. For patients who question whether less invasive testing is available, clinicians now have alternatives options to consider. Elastography and serum markers are two such diagnostic options reviewed in an editorial published in the June issue of Hepatology, a journal of the American Association for the Study of Liver Diseases.

2 Jun 2011

Octomom’s fertility specialist loses license

A Beverly Hills fertility doctor who assisted Nadya Suleman in conceiving octuplets is set to lose his medical license, the Medical Board of California announced Wednesday.

2 Jun 2011

Protox reports net and comprehensive loss of $2.2 million for first quarter 2011

Protox Therapeutics Inc., a leader in the development of receptor targeted therapeutic fusion proteins, today announced financial results and achievements for the quarter ended March 31, 2011.

2 Jun 2011

Clovis Oncology, Roche partner to develop in vitro PCR-based diagnostic test for NSCLC

Clovis Oncology, Inc. and Roche, announced today that they have entered into an agreement to develop an in vitro PCR based companion diagnostic test.

2 Jun 2011

OncoSec Medical to present results of ElectroImmunotherapy clinical trial in melanoma at ASCO 2011

OncoSec Medical Incorporated, which is developing its advanced-stage ElectroOncology therapies to treat solid tumor cancers, announced today that one of its clinical trial advisers will present results from an ElectroImmunotherapy clinical trial for melanoma at the 2011 American Society of Clinical Oncology Annual Meeting to be held June 4-8 at McCormick Place, Chicago, IL.

2 Jun 2011

Final analysis of AVEO's tivozanib Phase 2 trial on kidney cancer patients presented at ASCO 2011

AVEO Pharmaceuticals, Inc., today announced data from the final analysis of its Phase 2 randomized discontinuation trial evaluating tivozanib, its lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, in patients with advanced renal cell carcinoma.

2 Jun 2011

HHS to reduce rates for high-risk insurance pools

The Obama administration on Tuesday took steps in the 18 states where the federal government runs high-risk insurance pools to make coverage more affordable to people with pre-existing conditions.

2 Jun 2011

Microscopic worms in space

A space flight by millions of microscopic worms could help us overcome the numerous threats posed to human health by space travel. The Caenorhabditis elegans (C. elegans) have also given experts an insight into how to block muscle degradation in the sick and elderly.

2 Jun 2011

People with individual health coverage have highest cancer costs

One of every seven cancer patients spends more than 20 percent of his income on health care and insurance, according to a new study from federal researchers.

2 Jun 2011

AVEO’s ficlatuzumab-gefitinib Phase 1b/2 trial data against NSCLC to be presented at ASCO 2011

AVEO Pharmaceuticals, Inc. today announced results from the Phase 1b portion of its Phase 1b/2 clinical study of ficlatuzumab in combination with gefitinib in Asian subjects with non-small cell lung cancer.

2 Jun 2011

WHO warns of tobacco dangers on World No Tobacco Day

"Tobacco will kill nearly six million people this year, including 600,000 non-smokers, because governments are not doing enough to persuade people to quit or protect others from second-hand smoke, the World Health Organization (WHO) said on Tuesday," which was observed as World No Tobacco Day, Reuters/Toronto Sun reports.

2 Jun 2011

Loyola to offer free lecture on anterior-approach hip replacement surgery

On Tuesday, June 14th, Dr. Michael Stover of Loyola University Health System will give a free lecture in Burr Ridge on the muscle-preserving anterior-approach hip replacement surgery.

2 Jun 2011

Symphogen's rozrolimupab Phase 2 data to be presented at European Hematology Association meeting

Symphogen announced today that Phase 2 data will be presented from an open-label, multi-center clinical trial evaluating the safety and tolerability of rozrolimupab in adult, RhD positive, non-splenectomized patients with Immune thrombocytopenia (ITP) at the 16th Congress of the European Hematology Association meeting in London, UK on June 10 from 5:45 to 7:00 PM.

2 Jun 2011

WHO/IARC say mobile phone use may increase risk of certain brain cancers

Mobile phone use "may increase the risk of certain types of brain cancer in humans," therefore "consumers should consider ways of reducing their exposure," a WHO/International Agency for Research on Cancer (IARC) working group concluded on Tuesday, Reuters reports.

2 Jun 2011

Cell phone use poses no cancer risk, says JunkScience publisher

Today's media hoopla about the World Health Organization classifying cell phone use as "possibly carcinogenic" is much ado about nothing. The studies the WHO relies on are weak association studies that have zero reliability.

2 Jun 2011

Repligen announces completion of RG1068 pre-New Drug Application meeting with U.S. FDA

Repligen Corporation today announced that the Company has concluded a pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration related to its lead product candidate, RG1068 for improvement of magnetic resonance imaging of the pancreas.

2 Jun 2011

Positive results from Nuvilex European Phase II trial against pancreatic cancer

Nuvilex, Inc. announces the favorable results of a completed Phase II clinical trial carried out in Europe against pancreatic cancer. The treatment technology used in this trial was recently acquired by Nuvilex.

2 Jun 2011

Patients with advanced NSCLC can benefit from less toxic combination of erlotinib, bevacizumab

The standard treatment for patients with advanced non-small cell lung cancer is a combination of two old-fashioned cytotoxic chemotherapy drugs. The combination, however, comes with substantial toxicity.

2 Jun 2011

Investigators to examine how Ephb2 gene causes ependymoma in children

Armed with new grant support, investigators at Nationwide Children's Hospital plan to examine how a common gene of the nervous system leads to the development of a devastating brain tumor, ependymoma.

2 Jun 2011

Five organizations receive IASLC travel awards to attend 14th World Conference on Lung Cancer

Five advocacy organizations from India, Australia and the United States have been granted travel awards by the International Association for the Study of Lung Cancer (IASLC) to send representatives to the 14th World Conference on Lung Cancer, July 3-7 in Amsterdam.

2 Jun 2011

Cancer News and Research

Latest Cancer News and Research

Noninvasive diagnostics may offer alternative to liver biopsy for assessing liver fibrosis

Octomom’s fertility specialist loses license

Protox reports net and comprehensive loss of $2.2 million for first quarter 2011

Clovis Oncology, Roche partner to develop in vitro PCR-based diagnostic test for NSCLC

OncoSec Medical to present results of ElectroImmunotherapy clinical trial in melanoma at ASCO 2011

Final analysis of AVEO's tivozanib Phase 2 trial on kidney cancer patients presented at ASCO 2011

HHS to reduce rates for high-risk insurance pools

Microscopic worms in space

People with individual health coverage have highest cancer costs

AVEO’s ficlatuzumab-gefitinib Phase 1b/2 trial data against NSCLC to be presented at ASCO 2011

WHO warns of tobacco dangers on World No Tobacco Day

Loyola to offer free lecture on anterior-approach hip replacement surgery

Symphogen's rozrolimupab Phase 2 data to be presented at European Hematology Association meeting

WHO/IARC say mobile phone use may increase risk of certain brain cancers

Cell phone use poses no cancer risk, says JunkScience publisher

Repligen announces completion of RG1068 pre-New Drug Application meeting with U.S. FDA

Positive results from Nuvilex European Phase II trial against pancreatic cancer

Patients with advanced NSCLC can benefit from less toxic combination of erlotinib, bevacizumab

Investigators to examine how Ephb2 gene causes ependymoma in children

Five organizations receive IASLC travel awards to attend 14th World Conference on Lung Cancer

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in